In recent years, the integration of immune checkpoint inhibitors (ICIs), targeting programmed cell death 1 (PD-1) and its ligand PD-L1, has emerged as a promising neoadjuvant treatment strategy for early-stage solid tumors, including breast cancer, lung cancer, and ESCC (4, 5). This evidence concerns the gene PDCD1 and breast carcinoma.